We describe the results of CP as adjuvant to standard treatment for COVID-19 infection with pneumonia in a group of 41 patients over 80 years of age with multiple comorbidities, and compare them with a control group of 82 similar patients. Here, CP is linked to susceptibility to pneumonia measurement.